Ionis Execs在收益和收入增长强劲的情况下出售股票,股票近73.65美元。 Ionis execs sold shares amid strong earnings and revenue growth, with stock near $73.65.

Ionis制药公司董事Joseph Wender于10月31日出售了11 200股,每股75.16美元,股份减少了14.89%,为64 035股,价值约481万美元。 Ionis Pharmaceuticals (IONS) Director Joseph Wender sold 11,200 shares on October 31 at $75.16 each, reducing his stake by 14.89% to 64,035 shares valued at about $4.81 million. 执行副总统理查德·盖里也在同一天出售了89 249股股票,将他的所有权削减近60%。 Executive Vice President Richard Geary also sold 89,249 shares on the same day, cutting his ownership by nearly 60%. 股票于星期一以73.65美元关闭,下降0.65美元,交易量增加。 The stock closed at $73.65 on Monday, down $0.65, with elevated trading volume. Ionis报告说,第三季度收入为每股0.80美元,殴打估计数为0.35美元,收入逐年增长17.2%,增至1.57亿美元。 Ionis reported third-quarter earnings of $0.80 per share, beating estimates by $0.35, and revenue rose 17.2% year-over-year to $157 million. 该公司的市场上限为119.3亿美元,P/E的负比率为43.58。 The company has a market cap of $11.93 billion and a negative P/E ratio of -43.58. 分析师保持"中等购买"的共识评级,目标为83.05美元,几家公司提高了目标,理由是其RNA向疗法如SPINRAZA,TEGSEDI和WAYLIVRA的增长潜力. Analysts maintain a "Moderate Buy" consensus rating with a target of $83.05, and several firms raised their targets, citing growth potential in its RNA-targeted therapies like SPINRAZA, TEGSEDI, and WAYLIVRA.